logo

For the Inventor, By the Inventor

London, United Kingdom

Cancer Research Technology Limited


USPTO Granted Patents = 268

% Expired Patents = 40.3



Trademarks = 2

Forward Citations = 1,585

Loading Chart...
Loading Chart...

522 inventors (with patents filed for the assignee):

goldMedal Ian James Collins (20 out of 41 patents)

silverMedal Dan Niculescu-Duvaz (18 out of 26 patents)

bronzeMedal Caroline Joy Springer (18 out of 41 patents)

4.  Julian Blagg (17 out of 21 patents)

5.  Swen Hoelder (16 out of 16 patents)

6.  Edward McDonald (16 out of 22 patents)

7.  Bernard Thomas Golding (15 out of 30 patents)

8.  Ian Robert Hardcastle (15 out of 16 patents)

9.  Allan Michael Jordan (15 out of 23 patents)

10.  Thomas Peter Matthews (14 out of 14 patents)

11.  Ion Niculescu-Duvaz (14 out of 16 patents)

12.  Alfonso Zambon (14 out of 15 patents)

13.  Richard Marais (14 out of 26 patents)

14.  Roger John Griffin (14 out of 20 patents)

15.  Sergio Quezada (13 out of 13 patents)


Core Competencies:
BCL6 Inhibitors
MDM2-P53 Interaction
Immunomodulatory Antibodies
PARG Inhibitory Compounds
Cancer Treatment
Tumor Detection
Angiogenesis Inhibition
Kinase Inhibitors
Target DNA Detection
Treg Depletion
Microsatellite Instability
Heat Shock Proteins

268 patents:

1. 12670970 - Variant detection (2026-06-30),
2. 12637659 - Expansion of non-haematopoietic tissue-resident gamma delta T cells and uses of these cells (2026-05-26),
3. 12637428 - Isoquinoline derivatives as SIK2 inhibitors (2026-05-26),
4. 12528826 - [1,4]oxazepino[2,3-c]quinolinone derivatives as BCL6 inhibitors (2026-01-20),
5. 12509457 - Bicyclic nitrogen containing heterocycles as inhibitors of salt-induced kinase SIK2 (2025-12-30),
6. 12486285 - BCL6 inhibitors (2025-12-02),
7. 12478601 - DIETARY PRODUCT DEVOID OF AT LEAST TWO NON ESSENTIAL AMINO ACIDS (2025-11-25),
8. 12387819 - Enhanced detection of target DNA by fragment size analysis (2025-08-12),
9. 12367980 - Methods for predicting treatment response in cancers (2025-07-22),
10. 12129236 - PARG inhibitory compounds (2024-10-29),
11. 12110286 - Benzimidazolone derived inhibitors of BCL6 (2024-10-08),
12. 12109184 - Personalized methods of treating cancer (2024-10-08),
13. 12077526 - Isoindolinone inhibitors of the MDM2-P53 interaction and process for making them (2024-09-03),
14. 12071429 - Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity (2024-08-27),
15. 12042477 - Dietary product devoid of at least two non essential amino acids (2024-07-23),
Company Overview
Cancer Research Technology Limited, based in London, specializes in the development of innovative cancer therapies. The company focuses on a range of advanced technologies, including BCL6 inhibitors, MDM2-P53 interaction modulators, and immunomodulatory antibodies. Their research encompasses critical areas such as cancer treatment, tumor detection, and angiogenesis inhibition, aiming to enhance therapeutic outcomes for patients. By leveraging cutting-edge science, they contribute significantly to the fight against cancer through targeted and effective treatment solutions.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

268 Patents

#23 in London

#57 in United Kingdom

#3,278 in the World

London, GB
London, United Kingdom

Cancer Research Technology Limited

Forward Citations = 1,585

522 inventors:

goldMedal Ian James Collins (20 out of 41 patents)

silverMedal Dan Niculescu-Duvaz (18 out of 26 patents)

bronzeMedal Caroline Joy Springer (18 out of 41 patents)

4.  Julian Blagg (17 out of 21 patents)

5.  Swen Hoelder (16 out of 16 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Cancer Research Technology Limited. Retrieved from https://idiyas.com/company/cancer-research-technology

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…